Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
Clinical trial NCT03276962 · COMPLETED
Trial details
- NCT number
- NCT03276962
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-28
- Primary completion
- 2019-11-04
- Enrollment
- 1500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.